Spironolactone Monotherapy in Various Clinical Contexts
Hypertension
- The European Society of Cardiology recommends spironolactone as an add-on to existing multidrug regimens for resistant hypertension, demonstrating significant blood pressure reductions of approximately 21.7/8.5 mmHg without requiring loop diuretics 1
- Monitoring of serum potassium and creatinine is necessary before initiation and periodically thereafter, especially in patients on ACE inhibitors or ARBs, as hyperkalemia risk increases 1, 5, 6
Cirrhotic Ascites
- The American Association for the Study of Liver Diseases recommends spironolactone monotherapy as the preferred first-line approach for cirrhotic ascites, with furosemide added only if needed 7, 8, 9
- Spironolactone directly targets secondary hyperaldosteronism in cirrhosis, the primary mechanism of sodium retention, and has been proven more effective than furosemide monotherapy in randomized trials 8, 9
- Initial combination therapy with spironolactone and furosemide may be considered for moderate-to-severe ascites or inpatients, to achieve faster ascites control and maintain normokalemia 7, 8
Heart Failure
- The American College of Cardiology recommends mineralocorticoid receptor antagonists, including spironolactone, as part of combination therapy for heart failure with reduced ejection fraction, not as monotherapy 2, 3, 4
- The standard regimen includes an ACE inhibitor/ARB, beta-blocker, and MRA, with loop diuretics added as needed for volume management 2, 3, 4
Glomerular Disease/Nephrotic Syndrome
- The International Society of Nephrology recommends loop diuretics as first-line for edema management in nephrotic syndrome, with spironolactone used as adjunctive therapy 10
- Spironolactone is added for synergistic effect in resistant edema and to counter hypokalemia from loop/thiazide diuretics 10